Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Five Prime Therapeutics, Inc is a biotechnology business based in the US. Five Prime Therapeutics shares (FPRX) are listed on the NASDAQ and all prices are listed in US Dollars. Five Prime Therapeutics employs 87 staff and has a trailing 12-month revenue of around USD$18 million.
Since the stock market crash in March caused by coronavirus, Five Prime Therapeutics's share price has had significant positive movement.
Its last market close was USD$20.83, which is 74.27% up on its pre-crash value of USD$5.36 and 1,090.29% up on the lowest point reached during the March crash when the shares fell as low as USD$1.75.
If you had bought USD$1,000 worth of Five Prime Therapeutics shares at the start of February 2020, those shares would have been worth USD$468.08 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$4,028.94.
|Latest market close||USD$20.83|
|52-week range||USD$1.75 - USD$7.34|
|50-day moving average||USD$4.6059|
|200-day moving average||USD$4.6952|
|Wall St. target price||USD$8.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.486|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-23)||19.30%|
|1 month (2020-10-30)||356.80%|
|3 months (2020-08-28)||379.95%|
|6 months (2020-05-29)||293.02%|
|1 year (2019-11-29)||431.38%|
|2 years (2018-11-30)||62.23%|
|3 years (2017-11-30)||-20.95%|
|5 years (2015-11-30)||-45.83%|
Valuing Five Prime Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Five Prime Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Five Prime Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.14. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Five Prime Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||USD$18 million|
|Gross profit TTM||USD$-92,976,000|
|Return on assets TTM||-27.73%|
|Return on equity TTM||-63.99%|
|Market capitalisation||USD$219.8 million|
TTM: trailing 12 months
There are currently 1.7 million Five Prime Therapeutics shares held short by investors – that's known as Five Prime Therapeutics's "short interest". This figure is 3.6% up from 1.7 million last month.
There are a few different ways that this level of interest in shorting Five Prime Therapeutics shares can be evaluated.
Five Prime Therapeutics's "short interest ratio" (SIR) is the quantity of Five Prime Therapeutics shares currently shorted divided by the average quantity of Five Prime Therapeutics shares traded daily (recently around 303774.60035524). Five Prime Therapeutics's SIR currently stands at 5.63. In other words for every 100,000 Five Prime Therapeutics shares traded daily on the market, roughly 5630 shares are currently held short.
However Five Prime Therapeutics's short interest can also be evaluated against the total number of Five Prime Therapeutics shares, or, against the total number of tradable Five Prime Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Five Prime Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Five Prime Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0613% of the tradable shares (for every 100,000 tradable Five Prime Therapeutics shares, roughly 61 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Five Prime Therapeutics.
Find out more about how you can short Five Prime Therapeutics stock.
We're not expecting Five Prime Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Five Prime Therapeutics's shares have ranged in value from as little as $1.75 up to $7.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Five Prime Therapeutics's is 2.5389. This would suggest that Five Prime Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.
Everything we know about the Qilian International Holding Group IPO, plus information on how to buy in.
Everything we know about the AbCellera Biologics IPO, plus information on how to buy in.
Steps to owning and managing CALM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BG, with 24-hour and historical pricing before you buy.
Steps to owning and managing BCLI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLBD, with 24-hour and historical pricing before you buy.
Steps to owning and managing BDTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RILYO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASPN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.